EUVIMEDEUVIMED entdecken
Open Access

The interplay mechanism between IDH mutation, MGMT-promoter methylation, and PRMT5 activity in the progression of grade 4 astrocytoma: unraveling the complex triad theory

Maher Kurdi, Alaa Alkhotani, Abdulrahman Sabbagh, Eyad Faizo, Ahmed I Lary, Ahmed K Bamaga, Majid Almansouri, Badr Hafiz, Thamer Alsharif, Saleh Baeesa

Oncology Research · 2024

DOI: 10.32604/or.2024.051112 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Oncology Research, 2024. Verfasst von Maher Kurdi und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Faculty of Medicine, King Abdulaziz University, Rabigh, Saudi Arabia. Hauptthemen laut MEDLINE: Astrocytoma, Brain Neoplasms, Isocitrate Dehydrogenase, Promoter Regions, Genetic. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The dysregulation of Isocitrate dehydrogenase (IDH) and the subsequent production of 2-Hydroxyglutrate (2HG) may alter the expression of epigenetic proteins in Grade 4 astrocytoma. The interplay mechanism between IDH, O-6-methylguanine-DNA methyltransferase (MGMT)-promoter methylation, and protein methyltransferase proteins-5 (PRMT5) activity, with tumor progression has never been described.

Methods

A retrospective cohort of 34 patients with G4 astrocytoma is classified into IDH-mutant and IDH-wildtype tumors. Both groups were tested for MGMT-promoter methylation and PRMT5 through methylation-specific and gene expression PCR analysis. Inter-cohort statistical significance was evaluated.

Results

Both IDH-mutant WHO grade 4 astrocytomas (n = 22, 64.7%) and IDH-wildtype glioblastomas (n = 12, 35.3%) had upregulated PRMT5 gene expression except in one case. Out of the 22 IDH-mutant tumors, 10 (45.5%) tumors showed MGMT-promoter methylation and 12 (54.5%) tumors had unmethylated MGMT. All IDH-wildtype tumors had unmethylated MGMT. There was a statistically significant relationship between MGMT-promoter methylation and IDH in G4 astrocytoma (p-value = 0.006). Statistically significant differences in progression-free survival (PFS) were also observed among all G4 astrocytomas that expressed PRMT5 and received either temozolomide (TMZ) or TMZ plus other chemotherapies, regardless of their IDH or MGMT-methylation status (p-value=0.0014). Specifically, IDH-mutant tumors that had upregulated PRMT5 activity and MGMT-promoter methylation, who received only TMZ, have exhibited longer PFS.

Conclusions

The relationship between PRMT5, MGMT-promoter, and IDH is not tri-directional. However, accumulation of D2-hydroxyglutarate (2-HG), which partially activates 2-OG-dependent deoxygenase, may not affect their activities. In IDH-wildtype glioblastomas, the 2HG-2OG pathway is typically inactive, leading to PRMT5 upregulation. TMZ alone, compared to TMZ-plus, can increase PFS in upregulated PRMT5 tumors. Thus, using a PRMT5 inhibitor in G4 astrocytomas may help in tumor regression.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AstrocytomaBrain NeoplasmsIsocitrate DehydrogenasePromoter Regions, GeneticProtein-Arginine N-MethyltransferasesTumor Suppressor ProteinsAdultAgedFemaleHumansMaleMiddle AgedDisease ProgressionDNA MethylationDNA Modification MethylasesDNA Repair EnzymesGene Expression Regulation, NeoplasticMutationNeoplasm GradingRetrospective StudiesTemozolomide

Stichwörter der Autor:innen

GlioblastomaGrade 4 astrocytomaIsocitrate dehydrogenase (IDH)O-6-methylguanine-DNA methyltransferase (MGMT)Progression-free survival (PFS)Protein methyltransferase proteins-5 (PRMT5)

Substanzen

DNA Modification MethylasesDNA Repair EnzymesIsocitrate DehydrogenaseMGMT protein, humanPRMT5 protein, humanProtein-Arginine N-MethyltransferasesTemozolomideTumor Suppressor Proteins

Autor:innen und Institutionen

  • Department of Pathology, Faculty of Medicine, King Abdulaziz University, Rabigh, Saudi Arabia.
  • Department of Pathology, College of Medicine, Umm Al-Qura University, Makkah, Saudi Arabia.
  • Department of Surgery, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia.
  • Department of Surgery, Faculty of Medicine, University of Tabuk, Tabuk, Saudi Arabia.
  • Section of Neurosurgery, Department of Surgery, King Abdulaziz Medical City, Jeddah, Saudi Arabia.
  • Department of Pediatrics, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia.

Zitieren

APA

Kurdi, M., Alkhotani, A., Sabbagh, A., Faizo, E., Lary, A. I., Bamaga, A. K., Almansouri, M., Hafiz, B., Alsharif, T., & Baeesa, S. (2024). The interplay mechanism between IDH mutation, MGMT-promoter methylation, and PRMT5 activity in the progression of grade 4 astrocytoma: unraveling the complex triad theory. Oncology Research. https://doi.org/10.32604/or.2024.051112

Vancouver

Kurdi M, Alkhotani A, Sabbagh A, Faizo E, Lary AI, Bamaga AK, et al. The interplay mechanism between IDH mutation, MGMT-promoter methylation, and PRMT5 activity in the progression of grade 4 astrocytoma: unraveling the complex triad theory. Oncology Research. 2024. doi:10.32604/or.2024.051112

BibTeX
@article{Kurdi2024,
  author = {Kurdi, Maher and Alkhotani, Alaa and Sabbagh, Abdulrahman and Faizo, Eyad and Lary, Ahmed I and Bamaga, Ahmed K and Almansouri, Majid and Hafiz, Badr and Alsharif, Thamer and Baeesa, Saleh},
  title = {The interplay mechanism between IDH mutation, MGMT-promoter methylation, and PRMT5 activity in the progression of grade 4 astrocytoma: unraveling the complex triad theory},
  journal = {Oncology Research},
  year = {2024},
  doi = {10.32604/or.2024.051112}
}
Kostenlos starten →